<DOC>
	<DOCNO>NCT00399932</DOCNO>
	<brief_summary>Non-alcoholic fatty liver disease ( NAFLD ) recognise hepatic complication metabolic syndrome insulin resistance . In patient , disease progress steatohepatitis ( NASH ) associate fatty liver , hepatocellular damage , chronic inflammation variable progressive fibrosis . The latter evolve cirrhosis end-stage liver disease . Thus presence fibrosis sign severity disease , therefore accurate detection crucial identification patient need treatment appropriate follow-up . To date , histological examination biopsy liver gold standard diagnosis fibrosis . procedure however associate significant complication 0.01 0.1 % case sample error analyse minimal portion fo liver . The aim study evaluate , population patient metabolic syndrome , whether non-invasive test may identify hepatic fibrosis . At inclusion , serum test , fibroscan ( elastography liver ultra-sounds ) elastography MRI perform . Those test repeat within 2 month . A liver biopsy perform 2 3 ( serum test , fibroscan elastography ) test suggestive hepatic fibrosis . This study allow determine - whether hepatic fibrosis may detect non-invasive mean patient NAFLD/NASH . - whether correlation non-invase test liver biopsy assessment fibrosis severity - whether presence fatty liver interfere result fibroscan elastography . - whether metabolic factor associate increase risk fibrosis population .</brief_summary>
	<brief_title>Non-invasive Evaluation Hepatic Fibrosis Patients With Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<criteria>metabolic syndrome 3 5 criterion ( ATP III definition ) alcohol intake &gt; 20g/day ( woman ) , &gt; 30g/day ( men ) chronic liver disease cause : viral hepatitis ( HBV , HCV ) , Wilson 's disease , haemochromatosis , alpha1 antitrypsin deficiency , druginduced , ... decompensated cirrhosis ( ChildPugh 3 ) body weight &gt; 120 Kg</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>metabolic syndrome</keyword>
	<keyword>insulin resistance</keyword>
	<keyword>NASH</keyword>
	<keyword>hepatic fibrosis</keyword>
	<keyword>Fibroscan</keyword>
	<keyword>elastography MRI</keyword>
</DOC>